218 related articles for article (PubMed ID: 31434916)
1. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
[TBL] [Abstract][Full Text] [Related]
2. Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.
Yousif AM; Minopoli M; Bifulco K; Ingangi V; Di Carluccio G; Merlino F; Motti ML; Grieco P; Carriero MV
PLoS One; 2015; 10(5):e0126172. PubMed ID: 25938482
[TBL] [Abstract][Full Text] [Related]
3. Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.
Yousif AM; Ingangi V; Merlino F; Brancaccio D; Minopoli M; Bellavita R; Novellino E; Carriero MV; Carotenuto A; Grieco P
Eur J Med Chem; 2018 Jan; 143():348-360. PubMed ID: 29202399
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.
Gargiulo L; Longanesi-Cattani I; Bifulco K; Franco P; Raiola R; Campiglia P; Grieco P; Peluso G; Stoppelli MP; Carriero MV
J Biol Chem; 2005 Jul; 280(26):25225-32. PubMed ID: 15866865
[TBL] [Abstract][Full Text] [Related]
6. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.
Bifulco K; Longanesi-Cattani I; Gargiulo L; Maglio O; Cataldi M; De Rosa M; Stoppelli MP; Pavone V; Carriero MV
FEBS Lett; 2008 Apr; 582(7):1141-6. PubMed ID: 18339322
[TBL] [Abstract][Full Text] [Related]
7. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Carriero MV; Longanesi-Cattani I; Bifulco K; Maglio O; Lista L; Barbieri A; Votta G; Masucci MT; Arra C; Franco R; De Rosa M; Stoppelli MP; Pavone V
Mol Cancer Ther; 2009 Sep; 8(9):2708-17. PubMed ID: 19706734
[TBL] [Abstract][Full Text] [Related]
9. The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.
Gorrasi A; Li Santi A; Amodio G; Alfano D; Remondelli P; Montuori N; Ragno P
PLoS One; 2014; 9(1):e86352. PubMed ID: 24466048
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.
He HQ; Troksa EL; Caltabiano G; Pardo L; Ye RD
J Biol Chem; 2014 Jan; 289(4):2295-306. PubMed ID: 24285541
[TBL] [Abstract][Full Text] [Related]
11. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Carriero MV; Bifulco K; Ingangi V; Costantini S; Botti G; Ragone C; Minopoli M; Motti ML; Rea D; Scognamiglio G; Botti G; Arra C; Ciliberto G; Pessi A
Sci Rep; 2017 May; 7(1):1312. PubMed ID: 28465589
[TBL] [Abstract][Full Text] [Related]
12. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
13. The formyl peptide fMLF primes platelet activation and augments thrombus formation.
Salamah MF; Ravishankar D; Vaiyapuri R; Moraes LA; Patel K; Perretti M; Gibbins JM; Vaiyapuri S
J Thromb Haemost; 2019 Jul; 17(7):1120-1133. PubMed ID: 31033193
[TBL] [Abstract][Full Text] [Related]
14. The role of water in activation mechanism of human N-formyl peptide receptor 1 (FPR1) based on molecular dynamics simulations.
Yuan S; Ghoshdastider U; Trzaskowski B; Latek D; Debinski A; Pulawski W; Wu R; Gerke V; Filipek S
PLoS One; 2012; 7(11):e47114. PubMed ID: 23189124
[TBL] [Abstract][Full Text] [Related]
15. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Ingangi V; Bifulco K; Yousif AM; Ragone C; Motti ML; Rea D; Minopoli M; Botti G; Scognamiglio G; Fazioli F; Gallo M; De Chiara A; Arra C; Grieco P; Carriero MV
Oncotarget; 2016 Aug; 7(34):54474-54487. PubMed ID: 27323409
[TBL] [Abstract][Full Text] [Related]
16. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
[TBL] [Abstract][Full Text] [Related]
17. UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.
Carriero MV; Bifulco K; Minopoli M; Lista L; Maglio O; Mele L; Di Carluccio G; De Rosa M; Pavone V
Mol Cancer Ther; 2014 May; 13(5):1092-104. PubMed ID: 24705350
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.
Khlebnikov AI; Schepetkin IA; Kirpotina LN; Brive L; Dahlgren C; Jutila MA; Quinn MT
J Mol Model; 2012 Jun; 18(6):2831-43. PubMed ID: 22127612
[TBL] [Abstract][Full Text] [Related]
19. The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.
Bifulco K; Longanesi-Cattani I; Gala M; DI Carluccio G; Masucci MT; Pavone V; Lista L; Arra C; Stoppelli MP; Carriero MV
J Thromb Haemost; 2010 Dec; 8(12):2789-99. PubMed ID: 20880257
[TBL] [Abstract][Full Text] [Related]
20. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
